ImmunityBio, Inc. Common Stock vs. Moderna, Inc. Common Stock
IBRX
ImmunityBio, Inc. Common Stock
$10.29 +10.83%
VS MRNAModerna, Inc. Common Stock
$190.01 +0.57%
Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| IBRX | MRNA | |
|---|---|---|
| Market Cap | $10.90 billion | $75.86 billion |
| Revenue (TTM) | — | $2.23 billion |
| Net Income (TTM) | — | $-3,151,000,000 |
MRNA leads on 1 of 1 size & scale factors.
Valuation
| IBRX | MRNA | |
|---|---|---|
| Price / Book | — | 11.22 |
| Price / Sales | — | 34.05 |
IBRX and MRNA split the valuation factors evenly.
Profitability
| IBRX | MRNA | |
|---|---|---|
| Net Margin | — | -141.43% |
| Return on Equity | — | -46.61% |
IBRX and MRNA split the profitability factors evenly.
Risk & Sentiment
| IBRX | MRNA | |
|---|---|---|
| Short Interest | 0.42% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: IBRX overview, IBRX financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.